readthroughSign in
Nov 12, 2026Quarterly update

Aktis Oncology opens third Phase 1b trial, reports Q3 2026 results

The company started a new lung cancer study of AKY-2519 and began backfill dosing in its two other mid-stage trials while reporting $492.9 million in cash as of September 30, 2026.

Aktis Oncology reported business updates and financial results for the quarter ended September 30, 2026 in a release dated November 12, 2026. The company initiated the Phase 1b BActinium-2 trial evaluating AKY-2519 in patients with non-small cell lung cancer and other B7-H3 expressing solid tumors.1 This marks a third ongoing clinical trial, as CEO Matthew Roden noted the company now has three clinical trials underway in the U.S. across two targets, Nectin-4 and B7-H3.1

In its other two studies, Aktis began backfill cohorts. For AKY-1189, the company started backfill dosing at the 6 MBq level to gather more safety and antitumor activity data in up to 30 patients, the first of up to two dose levels planned for backfill.1 For AKY-2519 in the BActinium-1 prostate cancer trial, backfill began at the 9 MBq dose level in both PLUVICTO-naïve and PLUVICTO-experienced cohorts, each enrolling up to 30 patients, as the first of up to two planned backfill dose levels in each population.1

On timing, the company said it expects preliminary data from the NECTINIUM-2 trial in the first quarter of 20271 and preliminary data from the BActinium-1 trial in 2027.1 It also reported progress on manufacturing, saying it began manufacturing drug product in its in-house GMP facility and intends to amend the INDs for both programs to include that facility as a manufacturer.1

On finances, Aktis said cash, cash equivalents, and marketable securities were $492.9 million as of September 30, 2026, compared with $226.8 million at the end of 2025.1 The company stated this is expected to fund its operating plan into 2029.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.